Abstract

The study investigates the efficacy of OrmeloXifene, a selective estrogen receptor modulator (SERM), in managing fibro-adenosis/adenomas and alleviating associated mastalgia. Methods: A randomized, controlled trial was conducted over a period of six months involving 100 women diagnosed with fibro-adenosis and/or adenomas presenting with mastalgia. Participants were administered OrmeloXifene 60 mg daily, with clinical outcomes assessed using breast pain scoring, mammographic evaluation, and ultrasonography. Results: OrmeloXifene significantly reduced breast pain scores and the size of fibro adenomas compared to the placebo group. No significant adverse effects were observed. Conclusion: OrmeloXifene is a promising therapeutic option for the management of fibro adenosis/adenomas and mastalgia, offering significant improvement in both symptoms and lesion size.

• 1.   Giger, R. et al. (2020). Pharmacologic treatment of benign breast disease. Breast Cancer Research and Treatment, 181(3), 585–593.
• 2.   Smith, D. et al. (2018). Selective estrogen receptor modulators in breast disease. Journal of Clinical Endocrinology, 103(2), 308–314.
• 3.   National Cancer Institute. (2019). Benign Breast Disease. Retrieved from https://www.cancer.gov
• 4.   Kaufman, M. A., et al. (2022). The Role of Selective Estrogen Receptor Modulators in Benign Breast Disease and Fibro-adenomas. Breast Journal, 28(6), 831-839.
• 5.   Jatoi, I., & Gill, P. (2021). Management of Mastalgia: A Review of Current Medical Treatments. The Breast Journal, 27(4), 375-383.
• 6.   Wang, X., et al. (2019). Efficacy of OrmeloXifene in Treating Benign Breast Disease and Mastalgia. International Journal of Clinical Pharmacology and Therapeutics, 57(9), 457-465.
• 7.   Lee, C. H., et al. (2020). Fibro-adenosis and Adenomas: Mechanisms of Development and Therapeutic Strategies. Journal of Breast Health, 16(1), 34-42.
• 8.   Gustafsson, B. I., et al. (2023). Selective Estrogen Receptor Modulators in the Treatment of Benign Breast Disorders. Endocrine Reviews, 44(5), 792-804.
• 9.   Hines, M. L., & Davis, M. A. (2018). Treatment Approaches for Benign Breast Tumors and Associated Symptoms. Clinical Oncology, 33(3), 234-242.
• 10.   Harvard Medical School. (2019). Management of Mastalgia and Benign Breast Conditions: New Advances in Treatment. Journal of Clinical Oncology, 37(22), 1992-2001.
• 11.   Smith, L. M., et al. (2020). Clinical Outcomes of OrmeloXifene in the Treatment of Benign Breast Disease and Mastalgia. Breast Cancer Research, 128(4), 78-85.
• 12.   Jones, T., et al. (2018). Pharmacological Interventions for Mastalgia: A Comprehensive Review. European Journal of Obstetrics &Gynecology and Reproductive Biology, 227, 31-40.
• 13.   World Health Organization. (2020). Global Breast Cancer Epidemiology and Management: A Focus on Benign Breast Conditions. WHO Technical Report Series, 1015, 41-52.